| Document |
Document Title |
|
WO/2024/097846A1 |
Provided are pharmaceutical formulations comprising 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitors with improved solubility for oral administration. Also provides are pharmaceutical formulations comprising sele...
|
|
WO/2024/095006A1 |
The present invention relates to a therapeutic agent comprising an autoregulation element, preferably wherein the therapeutic agent is an antigen binding protein. Methods of treatment comprising use of said agent are also disclosed.
|
|
WO/2024/097829A1 |
Described herein are compositions for inhibiting a protease or coagulation target comprising a nucleic acid aptamer covalently linked to a small molecule inhibitor and methods for using the same to inhibit coagulation. Also provided are ...
|
|
WO/2024/093915A1 |
Provided are a protein comprising an amino acid sequence capable of binding to a substrate GPRP peptide fragment, a fibrinogen like protein 1 (FGL1) comprising the amino acid sequence, and a fibrinogen domain (FD) thereof, and an individ...
|
|
WO/2024/097571A1 |
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhib...
|
|
WO/2024/095012A1 |
The invention relates to a compound of formula (Ia) and related aspects.
|
|
WO/2024/097163A1 |
Methods of treating paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, or idiopathic immune complex-mediated glomerulonephritis using MASP-3 serine protease inhibitors are provided. In some embodiments, the MASP-3 serine p...
|
|
WO/2024/095053A1 |
The present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers. T...
|
|
WO/2024/097436A1 |
Compounds for modulating the activity and/or the expression of 5-aminolevulinic acid synthase (ALAS) affecting biological functions. In part, novel compounds and pharmaceutically acceptable salts and in part, methods for preparing the no...
|
|
WO/2024/097413A1 |
The present invention provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of formoterol or a pharmaceutically acceptable salt thereof (e.g., formot...
|
|
WO/2024/095213A1 |
The present disclosure provides nucleic acids, compositions and vectors containing and their use for effecting gene editing and/or gene expression alteration on sickle cell disease (SCD)-associated genes, e.g., in vivo. The present discl...
|
|
WO/2024/097932A1 |
Disclosed herein are compounds and methods for the prevention and/or treatment of hemoglobinopathies. Also provided herein are such compounds for use in such methods. Also disclosed herein are pharmaceutical compositions comprising such ...
|
|
WO/2024/097667A1 |
Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-
d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxeta
n-3-yl)pip...
|
|
WO/2024/087673A1 |
An antiplatelet drug, comprising a platelet inhibitory molecule, a linker, and a capture group. The capture group is a functional group of click chemistry reaction. The antiplatelet drug has good antiplatelet activity, and can be used in...
|
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
|
WO/2024/088302A1 |
The present disclosure relates to a use of Herombopag or a pharmaceutically acceptable salt thereof in treatment of tumor chemotherapy-induced thrombocytopenia. Specifically, the present disclosure relates to a disease treatment method, ...
|
|
WO/2024/087860A1 |
The present invention relates to a method for obtaining high-purity and high-stability recombinant human albumin by adding medium- and long-chain fatty acid ligands and removing a protein having charge heterogeneity by means of anion or/...
|
|
WO/2024/092232A1 |
The present disclosure provides a co-formulation that includes an antibody that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and/or N-acet...
|
|
WO/2024/092210A1 |
Provided herein are methods to treat fibrosis and/or inhibit angiogenesis.
|
|
WO/2024/084214A1 |
The invention relates to Von Willebrand Factor (VWF) antibodies, and particularly, although not exclusively, to antibodies which target the C1-C6 domain of VWF. The invention extends to compositions comprising the antibodies, including p...
|
|
WO/2024/085149A1 |
The present invention addresses the problem of providing a capsule particle manufacturing method. 　Provided is a method for manufacturing capsule particles by using a Taylor reactor.
|
|
WO/2024/083980A1 |
The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
|
|
WO/2024/084217A1 |
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein R1, B1, B2, B3, B4, B5, and...
|
|
WO/2024/085325A1 |
The present invention relates to a composition for alleviating, preventing, or treating diseases related to peritoneal fibrosis, comprising tiplaxtinin. The tiplaxtinin of the present invention has an excellent peritoneal EMT inhibitory ...
|
|
WO/2024/086835A1 |
The present disclosure relates to methods for treating blood transfusion-dependent hematological malignancy patients with oxygen reduced blood.
|
|
WO/2024/085725A1 |
The present invention pertains to a novel compound derivative and a pharmacological use thereof and specifically to a novel 1,1-dioxo-1,2-benzisothiazole derivative or novel 3-citryl-1H-pyrazole derivatives possessing antiplatelet activi...
|
|
WO/2024/084501A1 |
The present disclosure relates to crystalline forms of mitapivat, amorphous mitapivat mono sulfate, crystalline forms of mitapivat mono sulfate, and crystalline forms of mitapivat hemi sulfate. The present disclosure also relates to proc...
|
|
WO/2024/080373A1 |
This reagent for measuring activated partial thromboplastin time contains a polymer having 2-methacryloyloxyethyl phosphorylcholine as a structural unit. This blood coagulation time regulator for a lupus anticoagulant-positive blood spec...
|
|
WO/2024/080371A1 |
This blood coagulation time shortening agent for a blood specimen deficient in coagulation factor XII for activated partial thromboplastin time measurement uses, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphoryl...
|
|
WO/2024/080736A1 |
The present invention provides a feature related to a cored tablet combination preparation comprising clopidogrel or a pharmaceutically acceptable salt thereof and ilaprazole as active ingredients. The cored tablet combination preparatio...
|
|
WO/2024/079664A1 |
The disclosure provides compositions including a human milk oligosaccharide (HMO), as well as methods of using the same for reducing inflammation of the skin, treating or preventing psoriasis, acne, rosacea, eczema, erythema, UV radiatio...
|
|
WO/2024/077335A1 |
This invention relates to Factor IX variant polypeptides for administration to soft tissues.
|
|
WO/2024/077488A1 |
Use of a polygonum capitatum granular preparation in the preparation of drugs for clearing heat and promoting diuresis, inducing diuresis for treating stranguria, treating urinary tract infection or stones, treating pyelonephritis, detox...
|
|
WO/2024/077856A1 |
Provided in the present invention is the use of a TBX family transcription factor as a target in the preparation of a drug for treating ophthalmic diseases. In the present invention, the TBX family transcription factor is used as a targe...
|
|
WO/2024/076550A1 |
Disclosed is a method of using Netrin-1 (NTN1) driven rejuvenation of an aged hematopoietic system based on its shown dependency of reestablishing integrity of aged bone marrow niche and reactivating DNA damage response (DDR). NTN1 is sh...
|
|
WO/2024/077140A1 |
In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specif...
|
|
WO/2024/077153A1 |
The present disclosure provides for efficient ex vivo processes for generating megakaryocytes and/or platelets from human induced pluripotent stem cells (iPSCs). Cells and platelets generated according to the disclosure in various embodi...
|
|
WO/2024/075139A1 |
The present application relates to an improved process for the preparation of finerenone and intermediates thereof, which is represented by the following structural formula-I.
|
|
WO/2024/074705A1 |
The present invention relates to a method of enhancing gene therapy by using an enzyme effective to degrade or digest and/or inhibit or reduce effector function of serum antibodies in the subject. More particularly, the subject is one th...
|
|
WO/2024/077158A1 |
In various aspects and embodiments, the present disclosure provides methods for generating T cell populations for cell therapy, including T lymphocytes (T cells) and progenitor T cells. In various embodiments, the invention provides for ...
|
|
WO/2024/077148A1 |
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the plasminogen (PLG) gene, as well as methods of inhibiting expression of PLG, and methods of treating subjects that would benefit from reduction i...
|
|
WO/2024/077159A1 |
The present disclosure provides for efficient ex vivo processes for generating B cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or mo...
|
|
WO/2024/069200A2 |
A modified protein scaffold and use thereof The invention relates to a protein comprising a limited amino acid sequence of SEQ ID NO: 115, within which a segment of the general formula Ih-mod GX1CX1VX2X3X4X5 is present where X1 is any of...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/067626A1 |
A composite, comprising: 3-hydroxybutyric acid; and one or more of potassium 3-hydroxybutyrate, or calcium 3-hydroxybutyrate, or magnesium 3-hydroxybutyrate. A composite, wherein the anion comprises 3-hydroxyvaleric acid, and the cation ...
|
|
WO/2024/066596A1 |
Provided are a rehmannia and lycium root bark decoction water extract solution, a rehmannia and lycium root bark decoction water extract paste, a rehmannia and lycium root bark decoction preparation and a preparation method therefor, and...
|
|
WO/2024/068159A1 |
This application relates generally to the field of synthesis, formulations and perivascular treatment methods involving cyclic ester derivatives of everolimus.
|
|
WO/2024/073056A1 |
A pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial metabolite includes an effective amount of cucurbituril. A method of treating a patient with an elevated serum level of an intest...
|
|
WO/2024/070504A1 |
Provided is a blood storage composition which can prevent the contamination of a plasma layer with DNA derived from blood cells, and can prevent, compared to the amount of a plasma before storage, a decrease in the amount of a plasma aft...
|
|
WO/2024/061097A1 |
Provided are an anti-platelet aggregation medicament and use thereof. The medicament is a compound having a structure of formula I, or a pharmaceutically acceptable salt thereof, a solvate thereof, or a deuterated substance thereof. The ...
|
